Definium Therapeutics, Inc. (NASDAQ:DFTX) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) have been assigned an average recommendation of “Moderate Buy” from the twenty-one analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, nineteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $66.00.

A number of analysts have weighed in on DFTX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a report on Thursday, October 15th. Canaccord Genuity Group set a $78.00 price target on Definium Therapeutics and gave the company a “buy” rating in a research note on Tuesday, September 15th. JPMorgan Chase & Co. initiated coverage on Definium Therapeutics in a report on Friday, October 9th. They issued an “overweight” rating and a $84.00 price target for the company. Royal Bank Of Canada reiterated an “outperform” rating on shares of Definium Therapeutics in a research report on Monday, October 19th. Finally, Piper Sandler reissued an “overweight” rating and set a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a report on Friday, August 7th.

Definium Therapeutics Price Performance

Shares of Definium Therapeutics stock opened at $35.68 on Thursday. The firm has a fifty day simple moving average of $38.43 and a 200-day simple moving average of $29.05. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. Definium Therapeutics has a 1-year low of $10.46 and a 1-year high of $49.70. The stock has a market capitalization of $4.79 billion, a price-to-earnings ratio of -10.40 and a beta of 2.19.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). On average, sell-side analysts expect that Definium Therapeutics will post -3.08 earnings per share for the current year.

Insider Transactions at Definium Therapeutics

In other news, CEO Robert Barrow sold 31,550 shares of the stock in a transaction on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $1,153,783.50. Following the completion of the transaction, the chief executive officer owned 2,213,090 shares in the company, valued at approximately $80,932,701.30. This represents a 1.41% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Brandi Roberts sold 3,377 shares of the firm’s stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $123,496.89. Following the transaction, the chief financial officer directly owned 394,528 shares of the company’s stock, valued at $14,427,888.96. The trade was a 0.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 71,098 shares of company stock valued at $2,626,115 in the last ninety days. 2.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in DFTX. Wellington Management Group LLP acquired a new stake in Definium Therapeutics during the second quarter valued at approximately $138,755,000. Seven Fleet Capital Management LP bought a new stake in shares of Definium Therapeutics in the 2nd quarter valued at approximately $6,992,000. Sequoia Financial Advisors LLC bought a new stake in shares of Definium Therapeutics in the 2nd quarter valued at approximately $812,000. Arizona State Retirement System acquired a new position in shares of Definium Therapeutics in the 2nd quarter worth approximately $1,431,000. Finally, TD Waterhouse Canada Inc. acquired a new position in shares of Definium Therapeutics in the 2nd quarter worth approximately $1,592,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.